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We have generated MIN6 ␤-cells that stably overexpress cytosolic phospholipase A 2 (cPLA 2 ) and show a ninefold increase in cPLA 2 activity. Overexpression of cPLA 2 T he phospholipase A 2 proteins are a large family of enzymes, ubiquitously expressed, that catalyze the breakdown of glycerophospholipids releasing arachidonic acid. Cytosolic phospholipase A 2 (cPLA 2 ) isoforms, termed cPLA 2␣, cPLA 2␤ , and cPLA 2␥ , have been identified in many cell types, including the pancreas (1-3). The cPLA 2␣ and cPLA 2␤ isoforms require the binding of Ca 2ϩ at micromolar concentrations for full activity (3) (4) (5) , which makes them potential targets for nutrient-induced intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ) elevations in ␤-cells and is suggestive of a signal transduction role in the insulin secretory pathway. Arachidonic acid is an effective initiator of insulin secretion (6 -9) , and studies using cPLA 2 inhibitors have supported a stimulatory role for arachidonic acid in nutrient-induced insulin secretion (9, 10) . Thus, these earlier observations are consistent with cPLA 2 releasing arachidonic acid in a controlled fashion from membrane phospholipids during an insulin secretory response.
To date, studies examining the role of cPLA 2 and arachidonic acid in the exocytotic release of insulin have focused on short-term signaling. However, long-term exposure to high levels of fatty acids has been shown to be detrimental to ␤-cell function, in contrast to the stimulatory short-term effects of arachidonic acid and other fatty acids on the ␤-cell. Thus, in the Zucker diabetic rat, a model for type 2 diabetes, excess circulating fatty acid levels are thought to contribute to the development of the diabetic state (11) . In addition, sustained exposure to high levels of free fatty acids in vitro is reported to cause an inhibition of glucose-induced insulin secretion from rat islets (12, 13) and INS-1 (14) and MIN6 (15, 16) cells. In each of these studies, the effectiveness of nonnutrient secretagogues were unaffected, suggesting that metabolic pathways proximal to calcium entry are targeted by excess fatty acids. In support of this, several studies have observed a lowered mitochondrial membrane potential, impaired glucose-induced elevations in intracellular ATP levels, and upregulation of uncoupling protein-2 (UCP-2) (14, 16, 17) , all of which point to mitochondrial function being a key target for fatty acids.
We have examined the effect of cPLA 2␣ upregulation on the normal functioning of ␤-cells, using a DNA vector to overexpress the enzyme in the MIN6 insulin-secreting cell line. MIN6 cells that constitutively expressed a high level of cPLA 2 were found to display no response to nutrient stimulation in terms of [Ca 2ϩ ] i elevations and insulin secretion, although responses to depolarizing stimuli were largely unaffected. Because glucose-induced NAD(P)H generation was virtually abolished and UCP-2 levels were increased in these cells, we propose that elevations in endogenous arachidonic acid profoundly impair the secretory functioning of the ␤-cell, largely via upregulation of UCP-2 expression. This unexpected consequence of cPLA 2 overexpression may be relevant to lipotoxicity-induced failure of ␤-cell secretory responses.
RESEARCH DESIGN AND METHODS
MIN6 cells were obtained from Dr. Y. Oka and Prof. J.-I. Miyazaki (University of Osaka, Osaka, Japan). Tissue culture reagents, G418, and MMLV (Moloney murine leukemia virus) reverse transcriptase were obtained from Life Technologies (Paisley, U.K.). We purchased a Dynabeads Oligo(dT) 25 kit from Dynal (Oslo, Norway). Restriction endonucleases and a CellTiter-Glo ATP quantification kit were obtained from Promega (Madison, WI), and pcDNA3.1 was from Stratagene Europe (Amsterdam, the Netherlands). PCR primers were prepared in house (Molecular Biology Unit, King's College London), and RT-PCR was performed using a LightCycler rapid thermal cycler system from Roche Diagnostics (Lewes, Sussex, U.K.). General laboratory chemicals, including fura-2 acetoxymethylester, phosphatidylcholine, arachidonic acid, rhodamine 123, 3-aminopropyltriethoxysilane, forskolin, and phorbol myristate acetate were purchased from Sigma (Poole, Dorset, U.K.). Anti-cPLA 2 antibody was purchased from Biogenesis (Poole), the secondary antibody was from Pierce (Rockford, IL), and [3H]phosphatidylcholine L␣-stearoyl-2-arachidonyl ([3H]PC) was from NEN DuPont (Herts, U.K.). An Axiovert 135 research inverted microscope was obtained from Carl Zeiss (Welwyn Garden City, U.K.). Fluorescence spectroscopy was performed using a Perkin Elmer Instruments LS50B luminescence spectrometer (Beaconsfield, U.K.). A Veritas microplate luminometer was purchased from Turner Biosystems (Sunnyvale, CA). Vector construction, transfection of MIN6 cells, and selection of clones. Cytosolic PLA 2␣ sense expression constructs were made by gelpurifying cPLA 2 cDNA and ligating it to pcDNA3.1, essentially as described for construction of antisense cPLA 2␣ vectors (18) . MIN6 cells, grown in Dulbecco's modified Eagle's medium supplemented with 15% FCS, 100 units/ml penicillin, 100 g/ml streptomycin, and 2 mmol/l glutamine, were electroporated (2 kV/cm, 3 F) with HindIII-linearized cPLA 2 sense vector. Transfected cells were selected by growth in medium supplemented with 1 mg/ml G418. Colonies of G418-resistant cells were expanded for analysis, and the clone that showed the highest expression of cPLA 2 was selected for functional characterization. Passage-matched, nontransfected MIN6 cells were used as controls in all experiments because these cells perform similarly to MIN6 cells stably transfected with empty pcDNA3.1 (18) . cPLA 2 expression and activity. The levels of expression of cPLA 2 were assessed by PAGE and immunoblotting, essentially as described (18) , using polyclonal anti-cPLA 2 murine antibody and anti-mouse horseradish peroxidase-linked secondary antibody. cPLA 2 activity was measured as the release of [3H]arachidonic acid from the sn-2 position of [ 3 H]PC, as previously described for rat islets of Langerhans (19) . Briefly, extracts of passage-matched control or cPLA 2 -overexpressing MIN6 cells (2.5 ϫ 10 5 cells/observation) were incubated (25 l, 37°C, 10 min) with [ 3 H]PC (final concentration 2 mol/l, specific radioactivity 20 Ci/mmol) in the presence of 2 mmol/l dithiothreitol and 0.2% (vol/vol) ␤-mercaptoethanol to inhibit type I and type II PLA 2 activities and in the presence or absence of EGTA (1 mmol/l) or CaCl 2 (1 mmol/l) to inhibit or activate cPLA 2 activity, respectively. Reactions were terminated, and the lipid products were extracted by the addition of butanol (50 l, 4°C) containing phosphatidylcholine (1 mg/ml) and arachidonic acid (1 mg/ml). The products in the butanol phase were separated by thin-layer chromatography on silica plates developed using petroleumether/diethylether/ glacial acetic acid (70:30:1, vol/vol/vol). Products were visualized by iodine vapor, and [3H]arachidonic acid (Rf 0.62) was quantified by liquid scintillation spectroscopy. Ca 2؉ microfluorimetry. Agonist-evoked changes in cytosolic Ca 2ϩ were examined in MIN6 cells grouped within monolayer clusters (3-20 cells/ cluster) on 3-aminopropyltriethoxysilane-coated glass coverslips, essentially as described previously (18) . Insulin secretion. We have shown previously that MIN6 cells show an improved secretory output when configured as pseudoislet structures rather than dissociated cells (20) . We therefore carried out all secretion experiments using MIN6 cells configured as pseudoislets, using a dynamic multichamber perifusion system at 37°C, as described previously (18) . Real-time NAD(P)H autofluorescence. MIN6 cells adherent on 13 ϫ 22-mm glass coverslips were incubated in glucose-and serum-free Dulbecco's modified Eagle's medium supplemented with 1% (wt/vol) BSA for up to 3 h. The coverslips were washed three times with Krebs Ringer's phosphate buffer (136 mmol/l NaCl, 4.7 mmol/l KCl, 1.25 mmol/l MgSO 2 , 1.25 mmol/l CaCl 2 , 5 mmol/l NaH 2 PO 4 , 2 mmol/l NaHCO 2 , and 25 mmol/l HEPES, pH 7.2) and transferred to quartz cuvettes containing 3 ml Krebs Ringer's phosphate buffer in an LS50B luminescence spectrometer. The cell-coated coverslips were maintained at 37°C and oriented across the diagonal of the cuvette so that the cell monolayer was facing the excitation light and reflecting light away from the emission collection grating. Excitation was at 340 nm, and emission was measured as a trace at 450 nm. A 390-nm low-pass filter was included in the excitation channel to limit scattered light. Real-time rhodamine 123 fluorescence. MIN6 cells were investigated according to the above protocol, except that rhodamine 123 at a final concentration of 25 mol/l was added for the last 20 min of the 3-h preincubation period. Excitation was at 490 nm, and emission was measured as a trace at 530 nm, as described (21) . UCP-2 mRNA expression. Messenger RNA was isolated from control and cPLA 2 -overexpressing MIN6 cells using a Dynabeads Oligo(dT) 25 kit and was reverse transcribed essentially as described previously (18) . UCP-2 mRNA levels were quantified by real-time RT-PCR amplification using a LightCycler rapid thermal cycler system and expressed relative to ␤-actin mRNA levels in the same samples. Primers for mouse UCP-2 and ␤-actin mRNAs were as follows: UCP-2 sense 5Ј-GTC GGA GAT ACC AGA GCA CT-3Ј; UCP-2 antisense 5Ј-GTG ACC TGC GCT GTG GTA CT-3Ј; ␤-actin sense 5Ј-ACG GCC AAG TCA TCA CTA TTG-3Ј; and ␤-actin antisense 5Ј-AGC CAC CGA TCC ACA CAG A-3Ј. The predicted sizes of the UCP-2 and ␤-actin PCR products were 308 and 300 bp, respectively. Real-time PCR was performed in a 10-l volume essentially as described previously (18) . All PCR protocols included a 10-s denaturation step and then continued for 40 cycles consisting of a 95°C denaturation for 0 s, annealing for 10 s at 58°C (␤-actin) or 61°C (UCP-2), and a 72°C extension phase for 12 s (␤-actin) or 13 s (UCP-2). Fluorescence measurements were taken at 83°C (␤-actin) and 85°C (UCP-2) for 2 s to eliminate fluorescence from primer-dimer formation. The amplification products of both primer pairs were subjected to melting point analyses and subsequent gel electrophoresis to ensure specificity of amplification, and reaction products were cut from agarose gels, purified, and sequenced (18) . Glucose-induced ATP generation. The effect of glucose on the ATP content of control and cPLA 2 -overexpressing cells was assessed using a luciferasebased assay. Cells were cultured in white-walled 96-well microtiter plates at a density of 2 ϫ 10 4 cells/well and pre-equilibrated by incubation (2 h 37°C) in medium in the absence of glucose, followed by incubation (15 min, 37°C) in the presence or absence of a stimulatory concentration of glucose (20 mmol/l). ATP was extracted and measured using a CellTiter-Glo ATP quantification kit, according to the manufacturer's instructions. Data analysis. Data are expressed, where appropriate, as means Ϯ SE and were analyzed statistically using Student's t test, ANOVA, and Bonferroni's multiple comparison test as appropriate. Differences between treatments were considered significant at P Ͻ 0.05.
RESULTS
cPLA 2 expression and activity in MIN6 cells transfected with a cPLA 2 expression vector. G418-resistant ␤-cell clones were expanded and harvested after transfection with the plasmid coding for cPLA 2 , and Fig. 1A shows cPLA 2 expression in the clone that showed the highest cPLA 2 expression, compared with passage-matched control cells. This clone was used for all of the further experiments described in this article. The expression studies were confirmed by direct measurements of cPLA 2 enzyme activity in whole-cell extracts in which the Ca 2ϩ -dependent generation of [ 3 H]arachidonic acid from phosphatidylcholine was determined. In control cells cPLA 2 activity was 220.3 Ϯ 22.5 fmol ⅐ 10 min Ϫ1 ⅐ 10 6 cells Ϫ1 , and enzyme activity was markedly higher in extracts of stably transfected cPLA 2 -overexpressing cells (945 Ϯ 43% controls, P Ͻ 0.001, n ϭ 4). Tolbutamide and KCl-induced stimulus-response coupling in cPLA 2 -overexpressing cells. Cytosolic Analysis of both the secretory responses to tolbutamide and KCl and the capacity of potentiators to enhance insulin secretion were carried out in a perifusion system. It can be seen from Fig. 2 that both KCl ( Fig. 2A) and tolbutamide (Fig. 2B) significantly stimulated insulin secretion from MIN6 pseudoislets in which cPLA 2 had been overexpressed. However, the cPLA 2 -overexpressing cells failed to demonstrate an initial transient peak in secretion, and they showed a slower rise in secretory output that was not equal in magnitude to the control cells until 6 -8 min after exposure to the stimuli. Tolbutamide-and KClinduced secretory responses from both control and cPLA 2 - overexpressing pseudoislets were potentiated by the adenylate cyclase activator forskolin (10 mol/l) ( Fig. 2A) and the protein kinase C activator phorbol myristate acetate (500 nmol/l) (Fig. 2B) , with similar maximal secretory outputs obtained with control and cPLA 2 -overexpressing cells. Nutrient-induced stimulus-response coupling in cPLA 2 -overexpressing cells. Although cPLA 2 -stably transfected cells and passage-matched control MIN6 cells showed similar Ca 2ϩ responses to tolbutamide and KCl (Fig. 1) , responses of the two sets of cells to nutrients were markedly different. Thus, as expected, sustained elevations in [Ca 2ϩ ] i were observed in control MIN6 cell clusters in response to 20 mmol/l glucose or 10 mmol/l ␣-ketoisocaproate (KIC), a deamination product of leucine that directly enters the tricarboxylic acid cycle (17 of 28 and 30 of 32 cells responded to glucose and KIC, respectively, in four separate experiments) ( Fig. 3B and D) . However, the responsiveness to both glucose and KIC was dramatically reduced in cPLA 2 -overexpressing cells (2 of 52 and 3 of 40 cells responded to glucose and KIC, respectively, in 4 -6 separate experiments) (Fig. 3A and  C) . The number of cells exhibiting glucose-induced increases in Ca 2ϩ was increased in the presence of the cPLA 2 inhibitor methyl arachidonyl fluorophosphate (MAFP; 18 of 53 cells in five experiments) (Fig. 3E) , and the basal-to-peak change in Ca 2ϩ in these cells was not significantly different from control cells (cPLA 2 -overexpressing ϩ 50 mol/l MAFP: 0.74 Ϯ 0.31, n ϭ 18; control: 0.57 Ϯ 0.19, n ϭ 17; P Ͼ 0.2).
Perifusion experiments indicated that control MIN6 pseudoislets showed a characteristic first phase of secretion followed by a lower sustained response at ϳ300% above basal levels in response to stimulatory levels of glucose (20 mmol/l). In contrast, cPLA 2 -overexpressing cells showed only a small, short-lived response to glucose, with glucose-induced secretion significantly less at all time points (P Ͻ 0.01 vs. control) (Fig. 4) . The lack of secretion in response to 20 mmol/l glucose did not reflect insufficient insulin content, nor was it a consequence of abnormally elevated basal levels of insulin secretion because control and cPLA 2 -overexpressing cells had very similar insulin contents (sense: 1.24 Ϯ 0.1 ng insulin/pseudoislet; control: 1.06 Ϯ 0.06; n ϭ 6 -7, P Ͼ 0.1), and perifusion experiments indicated that overexpression of cPLA 2 did not significantly affect the rate of insulin secretion at 2 mmol/l glucose (sense: 0.25 Ϯ 0.01% insulin content; control: 0.26 Ϯ 0.02%; n ϭ 3, P Ͼ 0.2). Mitochondrial function in cPLA 2 -overexpressing cells. The severely diminished calcium and insulin secretory responses to glucose, but maintained responsiveness to depolarizing agents, in cPLA 2 -overexpressing cells are consistent with impairment of the metabolic changes that lead to closure of ATP-sensitive K ϩ (K ATP ) channels. The absence of KIC-induced elevations in Ca 2ϩ might suggest mitochondrial dysfunction, so oxidative metabolism was investigated in the control and cPLA 2 -upregulated cell populations using real-time NAD(P)H autofluorescence spectroscopy. Figure 5A shows that control MIN6 cells responded to 25 mmol/l glucose with a rapid and sustained rise in NAD(P)H autofluorescence, but in MIN6 cells overexpressing cPLA 2 the capacity of glucose to elevate intracellular NAD(P)H was diminished by ϳ95%. Disruption of the mitochondrial membrane potential ( m ) was apparent from studies using the dye rhodamine 123 to dynamically monitor m . In control MIN6 cells, 25 mmol/l glucose elicited an increase in m , detected as a decrease in rhodamine 123 fluorescence caused by mitochondrial uptake and quenching of this dye (22) . The addition of 10 mol/l p-(trifluoromethoxy) phenylylhydrazone (FCCP), an exogenous mitochondrial uncoupler, to control cells resulted in a rapid increase in rhodamine 123 fluorescence, consistent with dissipation of m and reduced dye quenching in the mitochondria. In MIN6 cells overexpressing cPLA 2 , the glucose-stimulated hyperpolarization of m was lost (Fig. 5B) . The pattern of NAD(P)H autofluorescence in the presence of 25 mmol/l glucose in cPLA 2 -overexpressing cells could be reproduced by adding 10 mol/l FCCP to control cells (Fig.  5C ), providing circumstantial evidence supporting increased mitochondrial uncoupling after upregulation of cPLA 2 .
The possibility that chronic overexpression of cPLA 2 in the MIN6 cells caused upregulation of the mitochondrial proton transporter UCP-2 was investigated by quantitative RT-PCR amplification of UCP-2 mRNA. These experiments indicated that mRNA for UCP-2 was significantly increased in the cPLA 2 -overexpressing MIN6 cells, and this could be reversed by 24-h exposure to 100 mol/l MAFP, a cPLA 2 inhibitor (Fig. 5D) . Glucose-induced ATP generation. Direct measurements of cellular ATP content confirmed a defect in glucose-induced ATP generation in the cPLA 2 -overexpressing MIN6 cells. Thus, in three separate experiments, glucose (20 mmol/l, 15 min) increased the ATP content of control cells (139.7 Ϯ 11.2% basal, P Ͻ 0.01). In contrast, exposure to 20 mmol/l glucose did not increase ATP in the cPLA 2 -overexpressing cells, but rather caused a small decrease in their ATP content (93.0 Ϯ 2.3% basal, P Ͻ 0.05).
DISCUSSION
One of the key events in stimulus-secretion coupling in response to elevations in extracellular glucose is an increase in [Ca 2ϩ ] i (23) , but the effector system(s) responsible for transducing this into an insulin secretory response has not been unequivocally established. An attractive candidate is cPLA 2 because its activity in ␤-cells is regulated by micromolar levels of calcium (24) . We have previously investigated the effects of underexpression of cPLA 2 in MIN6 cells and found that significantly reducing levels of cellular cPLA 2 had no effect on the cells' ability to initiate a secretory response, although it compromised insulin synthesis and/or packaging (18) . In the current study, we have investigated the effects of constitutive overexpression of cPLA 2 in MIN6 cells by stable transfection with a vector housing the full-length coding sequence for cPLA 2 driven by the cytomegalovirus promoter. Our measurements of cPLA 2 immunoreactive protein and enzyme activity confirm a stable increase in the expression and function of cPLA 2 in these cells.
It has recently been reported that short-term elevation in cPLA 2 in mouse primary ␤-cells stimulated exocytosis, as assessed by changes in membrane capacitance (9) . In those studies the stimulatory effects of cPLA 2 were mimicked by arachidonic acid and lysophosphatidylcholine in an additive manner, and they were ascribed to priming of insulin secretory granules through enhanced Cl Ϫ uptake. The effects of chronic overexpression of cPLA 2 on ␤-cell function described here are very different from those caused by transient (up to 24 h) upregulation (9) . Thus, in our studies there was no circumstance under which insulin secretion was enhanced in ␤-cell populations stably overexpressing cPLA 2 . The secretory responses to depolarizing stimuli (tolbutamide and KCl) were of a similar magnitude to those observed in passage-matched control cells, but they were slower in onset, perhaps suggesting that excess cPLA 2 has a restraining effect on the readily releasable pool of insulin. The most pronounced effect was the almost complete loss of insulin secretion in response to glucose by the cPLA 2 -overexpressing MIN6 cells. Consistent with this, glucose only elicited increases in [Ca 2ϩ ] i in 4% of the overexpressing cells. The responsiveness to glucose could be partially restored by inhibiting cPLA 2 activity with MAFP, suggesting that the elevated cPLA 2 activity was responsible for failure of the cells to respond to glucose. It is unlikely that the high levels of arachidonic acid associated with elevated cPLA 2 activity could have been responsible for the failure of the cells to respond to glucose with increases in [Ca 2ϩ ] i because arachidonic acid is known to stimulate increases in Ca 2ϩ in ␤-cells (25, 26) . However, arachidonic acid is metabolized by cyclo-oxygenases (COXs), and it is known both that COX-2 levels are high in MIN6 cells (27) and that metabolism of arachidonic acid via the COX pathway results in opening of K ATP channels (28) . This could provide one mechanism by which overexpression of cPLA 2 in ␤-cells could impair nutrient-induced elevations in Ca 2ϩ without affecting responses to agents that directly close K ATP channels or physically depolarize the cells.
Although our data indicate that an element of glucosestimulated elevations in Ca 2ϩ could be restored by inhibiting cPLA 2 activity, the majority of cells in microfluorimetry experiments were still unresponsive to glucose, in terms of elevations in Ca 2ϩ , even in the presence of MAFP. This suggests that cPLA 2 overexpression had produced additional perturbations of glucose-induced signaling that could not be reversed simply by short-term inhibition of cPLA 2 . Our observations that cPLA 2 -overexpressing cells also failed to show elevations in Ca 2ϩ in response to the mitochondrial substrate KIC suggest that the secretory defect lies downstream of glucose transport and glycolytic metabolism and places the focus on the mitochondrion as the locus of cPLA 2 -induced cellular dysfunction.
It is well known that chronic exposure of ␤-cells to high levels of fatty acids has a detrimental effect on normal cell function, resulting in reduced insulin secretory responses to nutrients but leaving responses to nonnutrients unaffected (12, 14, 15) . There is also good evidence that prolonged exposure to fatty acids impairs mitochondrial function; reduced mitochondrial membrane potential and cellular ATP levels have been observed after 24-to 96-h exposure of ␤-cells to fatty acids such as palmitate and oleate (14, 16) . In addition, studies performed using INS-1 insulin-secreting cells have indicated that long-term (48 -72 h) exposure to oleic acid increases both UCP-2 mRNA (14, 17, 29) and protein (14, 29) . The upregulation of UCP-2 is particularly relevant to ␤-cell (dys)function because it dissipates mitochondrial proton gradients, resulting in an insufficient membrane potential to drive ATP generation. It has been estimated that mitochondrial oxidative metabolism is responsible for up to 98% of the ATP that a ␤-cell produces (30), so interference with this process is likely to have deleterious effects on ␤-cell function. These observations of UCP-2 upregulation fit well with the phenotype of the cPLA 2 -overexpressing MIN6 cells and could provide a feasible explanation for the severe impairment of nutrient-stimulated responses, with largely intact responses to tolbutamide and KCl. Although there are no reports on the effects of chronic exposure of ␤-cells to arachidonic acid, there is convincing evidence that arachidonic acid exposure results in increased UCP-2 mRNA levels in skeletal muscle (31) and hepatocytes (32) . In the current study, mitochondrial dysfunction in the cPLA 2 -overexpressing MIN6 cells was indicated by a severely reduced increase in NAD(P)H autofluorescence upon exposure to 25 mmol/l glucose. In addition, cPLA 2 -overexpressing cells stained with rhodamine 123 did not exhibit an increase in m in response to glucose, in contrast to the clear response shown by passage-matched control cells. This is consistent with chronically elevated arachidonic acid uncoupling glucose metabolism from mitochondrial ATP generation, and it is further supported by our demonstration that exposure to stimulatory concentrations of glucose did not elevate the ATP content of cPLA 2 -overexpressing cells, in contrast to the expected increases in ATP seen in control cells.
In accordance with the measurements of NAD(P)H generation, m , and ATP levels, real-time quantitative RT-PCR indicated that UCP-2 expression was significantly increased in cPLA 2 -overexpressing cells, providing a link between arachidonic acid excess and mitochondrial uncoupling. Thus, UCP-2 mRNA levels were increased almost threefold in the cPLA 2 -overexpressing cells. Furthermore, incubation for 24 h in the presence of a cPLA 2 inhibitor nearly restored the levels of UCP-2 to those of control cells, suggesting that cPLA 2 activity was directly responsible for the increased UCP-2 expression. Overexpression of UCP-2 in islets has been reported to greatly reduce glucose-stimulated insulin secretion (33) , whereas islets from UCP-2 knockout mice displayed increased cellular ATP levels and enhanced insulin secretion (34) . In addition, chronic exposure of rat islets to high fatty acid levels resulted in impaired insulin secretion in response to glucose together with lowered ATP levels and an increase in UCP-2 protein levels (35) . The earlier observations made in UCP-2-overexpressing cells are entirely consistent with the phenotype of the MIN6 cells stably overexpressing cPLA 2 . Although earlier studies have suggested that upregulation of UCP-2 might be regulated by elevations in both glucose and free fatty acids (rev. in 36), it seems most likely that it is elevations in arachidonic acid resulting from cPLA 2 overexpression that are responsible for the upregulation of UCP-2 observed in our studies, because it was reversible by MAFP and because both the control cells and those overexpressing cPLA 2 were maintained in the same ambient glucose concentration.
In conclusion, our data suggest that excessive levels of intracellular arachidonic acid generated through long-term constitutive expression of cPLA 2 result in upregulation of UCP-2 and consequent mitochondrial uncoupling, thus greatly reducing the capacity of ␤-cells to respond to nutrients. This may well be relevant to ␤-cell failure, which can contribute to the onset of type 2 diabetes because chronic infusion of lipids rich in long-chain unsaturated fatty acids has recently been shown to reduce insulin secretion in individuals who are genetically predisposed to type 2 diabetes (37). Furthermore, MIN6 cells, in which intrinsically generated arachidonic acid has produced a selective loss of secretory responsiveness to nutrient stimuli, may offer a useful experimental model in which to further study the pathogenesis of this process.
